General American Investors Co. Inc. Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN

General American Investors Co. Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 217.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,362 shares of the biopharmaceutical company’s stock after purchasing an additional 21,486 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.0% of General American Investors Co. Inc.’s investment portfolio, making the stock its 29th largest holding. General American Investors Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $17,634,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $31,000. Traub Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $38,000. Berbice Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $762.65 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The firm has a market capitalization of $80.15 billion, a P/E ratio of 18.26, a price-to-earnings-growth ratio of 1.96 and a beta of 0.39. The company has a fifty day simple moving average of $756.55 and a two-hundred day simple moving average of $645.80. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $12.46 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on REGN. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. HSBC assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 target price for the company. Citigroup boosted their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $784.77.

Insider Buying and Selling

In other news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 8,431 shares of company stock worth $5,733,521. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.